Predicting the in vivo performance of BCS class II/IV drugs using a combined in vitro – in silico approach Case study: Albendazole and Albendazole sulfoxide

Authors: Pettarin M, Kostewicz ES, Bolger MB
Conference: SLP MIDD+
Keywords: in silico, in vitro, metabolite, PBPK modeling, Pre-Clinical, SLP2021MIDD

General Objective

Use of in vitro biorelevant experimentation in combination with in silico PBPK modeling to accurately predict the plasma concentrations of Abendazole and its main metabolite Albendazole sulfoxide after the oral administration of a tablet formulation in the fasted state.

By Maximo Pettarin, Edmund Kostewicz & Michael Bolger

Download Slides

Presented at SLP MIDD+ Virtual Conference March 3-4, 2021